Serum samples from 539 subjects were screened for the presence of the anticentromere antibody on a human laryngeal carcinoma (HEp-2) cell line (Antibodies, Inc.). The antibody was present in 61 patients (11%), most of whom had features of limited scleroderma or the CREST syndrome (calcinosis cutis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia), either independently or in association with primary biliary cirrhosis. The antibody was rarely found in patients with rapidly advancing or diffuse scleroderma. The anticentromere antibody is therefore a useful prognostic indicator in patients with early scleroderma, as it may help to predict what pattern of scleroderma will evolve. Screening for this antibody should be conducted in all patients with Raynaud's phenomenon, primary biliary cirrhosis, and scleroderma. Other previous studies have indicated a similar disease specificity and prognostic importance of this antibody.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0025-6196(12)62059-x | DOI Listing |
Am J Reprod Immunol
December 2024
Department of Obstetrics and Gynecology, Reproductive Medicine, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba, Japan.
Introduction: Anticentromere autoantibodies are associated with refractory IVF/ET failure, but causality is unclear. Experimental models are needed.
Methods: Immature oocytes collected from 23-day-old mice were matured in vitro for 18 h in a culture medium containing an anti-human centromere protein A (CENP-A) polyclonal antibody, and those oocytes' maturity and chromosome/spindle structure were assessed.
Semin Arthritis Rheum
February 2025
Rheumatology Unit, Department of Medicine-DIMED, Padova University Hospital, 35128 Padova, Italy; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy. Electronic address:
Objectives: Anticentromere antibodies (ACA) are typically found in limited cutaneous systemic sclerosis (lcSSc), whereas patients with anti-topoisomerase I antibodies (ATA) usually exhibit diffuse cutaneous involvement (dcSSc). We aimed to investigate the clinical phenotype and outcome of ACA-dcSSc.
Methods: A systematic literature review was conducted (January 1970 to April 2023) across MEDLINE, Scopus and OVID, to define whether SSc patients (population) within the ACA-dcSSc subset (exposure) had higher/lower risk for major organ involvement (interstitial lung disease-ILD, pulmonary hypertension-PH, primary myocardial involvement-PMI, scleroderma renal crisis-SRC) and mortality (outcomes) compared to ACA-lcSSc and ATA-dcSSc.
Arthritis Care Res (Hoboken)
January 2025
The University of Sydney and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
Intern Emerg Med
October 2024
Department of Experimental and Clinical Medicine, Division of Internal Medicine, University of Florence, Careggi Hospital, Largo Brambilla 3, Florence, Italy.
Ann Med
December 2024
Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!